375 related articles for article (PubMed ID: 32396844)
1. Inositols in Polycystic Ovary Syndrome: An Overview on the Advances.
Facchinetti F; Unfer V; Dewailly D; Kamenov ZA; Diamanti-Kandarakis E; Laganà AS; Nestler JE; Soulage CO;
Trends Endocrinol Metab; 2020 Jun; 31(6):435-447. PubMed ID: 32396844
[TBL] [Abstract][Full Text] [Related]
2. Experts' opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond.
Facchinetti F; Appetecchia M; Aragona C; Bevilacqua A; Bezerra Espinola MS; Bizzarri M; D'Anna R; Dewailly D; Diamanti-Kandarakis E; Hernández Marín I; Kamenov ZA; Kandaraki E; Laganà AS; Monastra G; Montanino Oliva M; Nestler JE; Orio F; Ozay AC; Papalou O; Pkhaladze L; Porcaro G; Prapas N; Soulage CO; Stringaro A; Wdowiak A; Unfer V
Expert Opin Drug Metab Toxicol; 2020 Mar; 16(3):255-274. PubMed ID: 32129111
[No Abstract] [Full Text] [Related]
3. Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients.
Monastra G; Unfer V; Harrath AH; Bizzarri M
Gynecol Endocrinol; 2017 Jan; 33(1):1-9. PubMed ID: 27898267
[TBL] [Abstract][Full Text] [Related]
4. Inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: now and the future.
Laganà AS; Myers SH; Forte G; Naem A; Krentel H; Allahqoli L; Alkatout I; Unfer V
Expert Opin Drug Metab Toxicol; 2024; 20(1-2):61-72. PubMed ID: 38226638
[TBL] [Abstract][Full Text] [Related]
5. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios.
Nordio M; Basciani S; Camajani E
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5512-5521. PubMed ID: 31298405
[TBL] [Abstract][Full Text] [Related]
6. Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach.
Laganà AS; Garzon S; Casarin J; Franchi M; Ghezzi F
Trends Endocrinol Metab; 2018 Nov; 29(11):768-780. PubMed ID: 30270194
[TBL] [Abstract][Full Text] [Related]
7. Reflections on inositol(s) for PCOS therapy: steps toward success.
Nestler JE; Unfer V
Gynecol Endocrinol; 2015 Jul; 31(7):501-5. PubMed ID: 26177098
[TBL] [Abstract][Full Text] [Related]
8. Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives.
Paul C; Laganà AS; Maniglio P; Triolo O; Brady DM
Gynecol Endocrinol; 2016 Jun; 32(6):431-8. PubMed ID: 26927948
[TBL] [Abstract][Full Text] [Related]
9. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome.
Dinicola S; Chiu TT; Unfer V; Carlomagno G; Bizzarri M
J Clin Pharmacol; 2014 Oct; 54(10):1079-92. PubMed ID: 25042908
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: A randomized open-label study.
Kachhawa G; Senthil Kumar KV; Kulshrestha V; Khadgawat R; Mahey R; Bhatla N
Int J Gynaecol Obstet; 2022 Aug; 158(2):278-284. PubMed ID: 34624138
[TBL] [Abstract][Full Text] [Related]
11. Inositols' Importance in the Improvement of the Endocrine-Metabolic Profile in PCOS.
Wojciechowska A; Osowski A; Jóźwik M; Górecki R; Rynkiewicz A; Wojtkiewicz J
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752081
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS).
Fruzzetti F; Perini D; Russo M; Bucci F; Gadducci A
Gynecol Endocrinol; 2017 Jan; 33(1):39-42. PubMed ID: 27808588
[TBL] [Abstract][Full Text] [Related]
13. The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial.
Colazingari S; Treglia M; Najjar R; Bevilacqua A
Arch Gynecol Obstet; 2013 Dec; 288(6):1405-11. PubMed ID: 23708322
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis.
Zhao H; Xing C; Zhang J; He B
Reprod Health; 2021 Aug; 18(1):171. PubMed ID: 34407851
[TBL] [Abstract][Full Text] [Related]
15. Inositols: From Established Knowledge to Novel Approaches.
Dinicola S; Unfer V; Facchinetti F; Soulage CO; Greene ND; Bizzarri M; Laganà AS; Chan SY; Bevilacqua A; Pkhaladze L; Benvenga S; Stringaro A; Barbaro D; Appetecchia M; Aragona C; Bezerra Espinola MS; Cantelmi T; Cavalli P; Chiu TT; Copp AJ; D'Anna R; Dewailly D; Di Lorenzo C; Diamanti-Kandarakis E; Hernández Marín I; Hod M; Kamenov Z; Kandaraki E; Monastra G; Montanino Oliva M; Nestler JE; Nordio M; Ozay AC; Papalou O; Porcaro G; Prapas N; Roseff S; Vazquez-Levin M; Vucenik I; Wdowiak A
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638926
[TBL] [Abstract][Full Text] [Related]
16. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
Nordio M; Proietti E
Eur Rev Med Pharmacol Sci; 2012 May; 16(5):575-81. PubMed ID: 22774396
[TBL] [Abstract][Full Text] [Related]
17. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome.
Unfer V; Porcaro G
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):623-31. PubMed ID: 24898153
[TBL] [Abstract][Full Text] [Related]
18. Metabolic and hormonal effects of a combined Myo-inositol and d-chiro-inositol therapy on patients with polycystic ovary syndrome (PCOS).
Januszewski M; Issat T; Jakimiuk AA; Santor-Zaczynska M; Jakimiuk AJ
Ginekol Pol; 2019; 90(1):7-10. PubMed ID: 30756365
[TBL] [Abstract][Full Text] [Related]
19. High dose of d-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial.
Mendoza N; Galan MI; Molina C; Mendoza-Tesarik R; Conde C; Mazheika M; Diaz-Ropero MP; Fonolla J; Tesarik J; Olivares M
Gynecol Endocrinol; 2020 May; 36(5):398-401. PubMed ID: 31657275
[TBL] [Abstract][Full Text] [Related]
20. The Effects of Myo-Inositol and D-Chiro-Inositol in a Ratio 40:1 on Hormonal and Metabolic Profile in Women with Polycystic Ovary Syndrome Classified as Phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria.
Pustotina O; Myers SH; Unfer V; Rasulova I
Gynecol Obstet Invest; 2024; 89(2):131-139. PubMed ID: 38295772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]